Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ekso Bionics Holdings (EKSO) Accounts Payables (2016 - 2026)

Ekso Bionics Holdings has reported Accounts Payables over the past 13 years, most recently at $1.4 million for Q4 2025.

  • On a quarterly basis, Accounts Payables fell 7.8% to $1.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.4 million, a 7.8% decrease, with the full-year FY2025 number at $1.4 million, down 7.8% from a year prior.
  • Accounts Payables reached $1.4 million in Q4 2025 per EKSO's latest filing, down from $1.7 million in the prior quarter.
  • The five-year high for Accounts Payables was $3.2 million in Q2 2023, with the low at $1.3 million in Q3 2021.
  • The 5-year median for Accounts Payables is $1.9 million (2024), against an average of $2.1 million.
  • Peak YoY movement for Accounts Payables: soared 107.0% in 2021, then tumbled 41.38% in 2023.
  • Tracing EKSO's Accounts Payables over 5 years: stood at $3.1 million in 2021, then grew by 1.42% to $3.2 million in 2022, then tumbled by 41.38% to $1.8 million in 2023, then decreased by 15.97% to $1.6 million in 2024, then fell by 7.8% to $1.4 million in 2025.
  • According to Business Quant data, Accounts Payables over the past three periods came in at $1.4 million, $1.7 million, and $1.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.